ATE203913T1 - Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält - Google Patents

Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält

Info

Publication number
ATE203913T1
ATE203913T1 AT94916430T AT94916430T ATE203913T1 AT E203913 T1 ATE203913 T1 AT E203913T1 AT 94916430 T AT94916430 T AT 94916430T AT 94916430 T AT94916430 T AT 94916430T AT E203913 T1 ATE203913 T1 AT E203913T1
Authority
AT
Austria
Prior art keywords
cross
growth factor
linked gelatin
fibroblasts
gel preparation
Prior art date
Application number
AT94916430T
Other languages
English (en)
Inventor
Yoshito Ikada
Yasuhiko Tabata
Shigeki Hijikata
Makoto Tamura
Original Assignee
Kaken Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd filed Critical Kaken Pharma Co Ltd
Application granted granted Critical
Publication of ATE203913T1 publication Critical patent/ATE203913T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT94916430T 1993-05-31 1994-05-31 Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält ATE203913T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP15274993 1993-05-31
PCT/JP1994/000876 WO1994027630A1 (en) 1993-05-31 1994-05-31 Cross-linked gelatin gel preparation containing basic fibroblast growth factor

Publications (1)

Publication Number Publication Date
ATE203913T1 true ATE203913T1 (de) 2001-08-15

Family

ID=15547330

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94916430T ATE203913T1 (de) 1993-05-31 1994-05-31 Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält

Country Status (6)

Country Link
US (1) US6831058B1 (de)
EP (1) EP0702959B1 (de)
JP (1) JP3639593B2 (de)
AT (1) ATE203913T1 (de)
DE (1) DE69427908T2 (de)
WO (1) WO1994027630A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8603511B2 (en) * 1996-08-27 2013-12-10 Baxter International, Inc. Fragmented polymeric compositions and methods for their use
US6066325A (en) 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US6063061A (en) * 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
JP2011046749A (ja) * 1996-08-27 2011-03-10 Baxter Internatl Inc 癒着防止用の断片化重合体ヒドロゲルおよびそれらの調製
US7435425B2 (en) 2001-07-17 2008-10-14 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
AU736784B2 (en) * 1997-06-03 2001-08-02 Celltran Limited New medicaments based on polymers composed of methacrylamide-modified gelatin
WO2001022989A2 (en) 1999-09-30 2001-04-05 Kaken Pharmaceutical Co., Ltd. Method to enhance healing of sternum after sternotomy
WO2001030411A1 (fr) * 1999-10-26 2001-05-03 Kaken Pharmaceutical Co., Ltd. Materiau de traitement d'embolie vasculaire a base d'hydrogel et therapie correspondante
WO2002019887A2 (en) * 2000-09-05 2002-03-14 Technion Research And Development Foundation Ltd. Methods of repairing longitudinal bone defects
JP2003238439A (ja) * 2002-02-13 2003-08-27 Yasuhiko Tabata 虚血治療剤
KR100981443B1 (ko) * 2002-04-01 2010-09-13 가켄 세야쿠 가부시키가이샤 염기성 선유 아세포 증식 인자 함유 치과용 점조 제제
JP2004115413A (ja) * 2002-09-25 2004-04-15 Yasuhiko Tabata 冠状動脈狭窄または閉塞治療用徐放性製剤
JP2004123576A (ja) * 2002-09-30 2004-04-22 Medgel Corp 多血小板血漿を含有する徐放性製剤
US8834864B2 (en) 2003-06-05 2014-09-16 Baxter International Inc. Methods for repairing and regenerating human dura mater
JP4578067B2 (ja) * 2003-06-06 2010-11-10 宏 清水 局所医薬組成物
ES2339862T3 (es) * 2003-06-20 2010-05-26 Novartis Vaccines And Diagnostics, Inc. Compuestos de piridino 1,2-a-pirimidin-4-ona como agentes anticancerosos.
US7927626B2 (en) 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
JP4532092B2 (ja) * 2003-09-30 2010-08-25 泰彦 田畑 血管新生剤
CA2542041C (en) * 2003-10-10 2014-12-09 Cellular Bioengineering, Inc. Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artifical corneal transplants
JP2005218780A (ja) * 2004-02-09 2005-08-18 Menicon Co Ltd 薬物放出速度を制御し得る薬物徐放可能なヒドロゲル材料の製造方法
WO2005087257A1 (ja) * 2004-03-16 2005-09-22 Kaken Pharmaceutical Co., Ltd. 架橋ゼラチンゲルを担体とする軟骨組織修復治療剤
WO2005097166A1 (ja) * 2004-04-09 2005-10-20 Kaken Pharmaceutical Co., Ltd. ゼラチンゲルを担体とする糖尿病性神経障害治療剤
JP2005325075A (ja) * 2004-05-14 2005-11-24 Yasuhiko Tabata 架橋ゼラチンゲルを担体とする半月板損傷治療剤
US20080107703A1 (en) * 2005-02-14 2008-05-08 Yasuhiko Tabata Hydrogel For Medical Use
TWI374750B (en) * 2005-10-19 2012-10-21 Univ Osaka Therapeutic agent for use in regenerating dentin- dental pulp composite
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
KR20090017654A (ko) 2006-05-31 2009-02-18 백스터 인터내셔널 인코포레이티드 척수 수술에서 세포 내성장을 통제하고 조직 재생을 조절하는 방법
EP2052740A4 (de) * 2006-08-01 2009-11-11 Nichiban Kk Vernetzte mehrschichtige gelatinegelstruktur, träger für einen bioaktiven faktor, zubereitung zur freisetzung des bioaktiven faktors und herstellungsverfahren dafür
TWI436793B (zh) 2006-08-02 2014-05-11 巴克斯特國際公司 快速作用之乾密封膠及其使用和製造方法
WO2008047904A1 (fr) * 2006-10-20 2008-04-24 National University Corporation Nagoya University Agent thérapeutique pour vasculopathie périphérique oblitérante et utilisation
WO2008072379A1 (ja) * 2006-12-13 2008-06-19 Fujifilm Corporation 修飾された生体高分子の製造方法及び生体高分子の架橋方法
JP5047603B2 (ja) * 2006-12-15 2012-10-10 エア・ウォーター株式会社 ゼラチン成形物およびその製造方法
EP1961411A1 (de) * 2007-02-21 2008-08-27 FUJIFILM Manufacturing Europe B.V. Zusammensetzung mit gesteuerter Freisetzung
EP1961414A1 (de) * 2007-02-21 2008-08-27 FUJIFILM Manufacturing Europe B.V. Rekombinante Gelatine enthaltende Zusammensetzung mit gesteuerter Freisetzung
WO2008103043A1 (en) * 2007-02-21 2008-08-28 Fujifilm Manufacturing Europe B.V. Rgd containing recombinant gelatin
DE102007051059B4 (de) * 2007-10-18 2014-04-03 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Bioverbundmaterial für die kontrollierte Freisetzung von Wirkstoffen
US8790698B2 (en) 2007-10-30 2014-07-29 Baxter International Inc. Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects
ATE543507T1 (de) 2007-11-07 2012-02-15 Ono Pharmaceutical Co Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
CN102014973A (zh) 2008-02-29 2011-04-13 弗罗桑医疗设备公司 用于促进止血和/或伤口愈合的装置
WO2010089873A1 (ja) * 2009-02-05 2010-08-12 ニチバン株式会社 照射架橋水溶性高分子粒子及び照射架橋ゼラチン粒子並びにこれらの製造方法
WO2010128672A1 (ja) * 2009-05-07 2010-11-11 富士フイルム株式会社 遺伝子組み換えゼラチンを含む血管新生誘導剤
US9039783B2 (en) 2009-05-18 2015-05-26 Baxter International, Inc. Method for the improvement of mesh implant biocompatibility
US9162006B2 (en) 2009-06-16 2015-10-20 Baxter International Inc. Hemostatic sponge
US8895508B2 (en) 2009-07-24 2014-11-25 Yasuhiki Tabata Methods for corneal endothelial proliferation using bFGF sustained-release gelatin hydrogel particles
JP5514222B2 (ja) * 2009-11-02 2014-06-04 ニチバン株式会社 電離性放射線で架橋したヒドロゲルから成る生体内薬剤徐放用担体材料及びその製造方法
US20120225483A1 (en) * 2009-11-13 2012-09-06 Hitachi-High-Technologies Microsphere-Containing Cell Aggregate
WO2011079336A1 (en) 2009-12-16 2011-07-07 Baxter International Inc. Hemostatic sponge
SA111320355B1 (ar) 2010-04-07 2015-01-08 Baxter Heathcare S A إسفنجة لايقاف النزف
ES2682302T3 (es) 2010-06-01 2018-09-19 Baxter International Inc Proceso para la producción de composiciones hemostáticas secas y estables
AU2011260260B2 (en) 2010-06-01 2015-09-03 Baxter Healthcare S.A. Process for making dry and stable hemostatic compositions
MX344402B (es) 2010-06-01 2016-12-14 Baxter Int Inc * Proceso para elaborar composiciones hemostaticas secas y estables.
ES2938568T3 (es) 2011-10-11 2023-04-12 Baxter Int Composiciones hemostaticas
HK1201212A1 (en) 2011-10-11 2015-08-28 Baxter International Inc Hemostatic compositions
SG11201401878SA (en) 2011-10-27 2014-09-26 Baxter Int Hemostatic compositions
WO2013131520A2 (en) 2012-03-06 2013-09-12 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
RU2636240C2 (ru) 2012-06-12 2017-11-21 Ферросан Медикал Дивайсиз А/С Сухая гемостатическая композиция
US9347037B2 (en) * 2013-02-11 2016-05-24 Evan Masataka Masutani Methods and apparatus for building complex 3D scaffolds and biomimetic scaffolds built therefrom
EP2957287B1 (de) 2013-02-15 2019-04-03 KORTUC Inc. Strahlungs-/chemotherapiesensibilisator zur lokalen intratumoralen injektion und zur kontrollierten freisetzung von wasserstoffperoxid mit hydrogel als träger
EP3010419B1 (de) 2013-06-21 2020-05-20 Ferrosan Medical Devices A/S Vakuumerweiterte trockenzusammensetzung und spritze zum zurückhalten davon
JP6489485B2 (ja) 2013-12-11 2019-03-27 フェロサン メディカル デバイシーズ エイ/エス 押し出し増強因子を含んでいる乾燥組成物
CA2960309A1 (en) 2014-10-13 2016-04-21 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
RU2705905C2 (ru) 2014-12-24 2019-11-12 Ферросан Медикал Дивайсиз А/С Шприц для удерживания и смешивания первого и второго веществ
AU2016290433B2 (en) 2015-07-03 2018-05-24 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
US11207258B2 (en) 2016-01-25 2021-12-28 Suntory Holdings Limited Capsule containing functional substance and method for manufacturing said capsule
JP6820912B2 (ja) * 2016-03-28 2021-01-27 富士フイルム株式会社 製剤、製剤用部材およびそれらの製造方法
ES2968412T3 (es) 2018-05-09 2024-05-09 Ferrosan Medical Devices As Método para preparar una composición hemostática
JP2023015416A (ja) * 2019-12-27 2023-02-01 Eaファーマ株式会社 瘻孔治療用材料

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3923969A (en) * 1973-06-12 1975-12-02 Battelle Institut E V Carrier system for a drug with sustained release
US4785079A (en) * 1984-11-09 1988-11-15 The Salk Institute For Biological Studies Isolation of fibroblast growth factor
IL74715A0 (en) * 1984-03-27 1985-06-30 Univ New Jersey Med Biodegradable matrix and methods for producing same
JPH0759522B2 (ja) * 1985-12-27 1995-06-28 住友製薬株式会社 徐放性製剤の製造法
JP2587219B2 (ja) * 1986-06-10 1997-03-05 エーザイ株式会社 溶解遅延性のゼラチン製剤組成物
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5164410A (en) * 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
JPH01282394A (ja) 1988-05-10 1989-11-14 Toshiba Corp 電動機の張力制御装置
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
JPH0249734A (ja) * 1988-08-12 1990-02-20 Wakunaga Pharmaceut Co Ltd 新規組成物
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
US5298243A (en) * 1988-10-20 1994-03-29 Denki Kagaku Kogyo Kabushiki Kaisha Colony stimulating factor-gelatin conjugate
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
GB9014871D0 (en) * 1990-07-05 1990-08-22 Erba Carlo Spa Drug delivery system for administering growth factor
JP3135138B2 (ja) * 1990-12-19 2001-02-13 科研製薬株式会社 骨疾患治療剤
JPH05132426A (ja) * 1991-02-15 1993-05-28 Takeda Chem Ind Ltd 骨組織の形成促進剤
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
US5656598A (en) * 1994-03-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Use of fibroblast growth factors to stimulate bone growth
EP0881908B1 (de) * 1994-03-08 2004-06-16 Osteosa Inc. Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums

Also Published As

Publication number Publication date
DE69427908T2 (de) 2001-11-22
US6831058B1 (en) 2004-12-14
JP3639593B2 (ja) 2005-04-20
EP0702959A1 (de) 1996-03-27
DE69427908D1 (de) 2001-09-13
WO1994027630A1 (en) 1994-12-08
EP0702959B1 (de) 2001-08-08
EP0702959A4 (de) 1996-11-27

Similar Documents

Publication Publication Date Title
DE69427908D1 (de) Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält
DE69414626D1 (de) Helle Haarpflegezusammensetzung
CA2047154A1 (en) Hair dye composition and its application method
DE19775083I2 (de) 7-Piperazinyl-oder 7-Morpholino-4-oxo-chinolin-3-carbonsaeurederivate ihre Herstellung und ihre Verwendung als antimikrobielle Mittel
PT871476E (pt) Composicao seca de factor sanguineo compreendendo trealose
ATE89723T1 (de) Retinoide zur behandlung lichtgeschaedigter haut.
SE8603228L (sv) Sarlekningsmedel
ATE207761T1 (de) Insulin formulierung
DE3788840D1 (de) Wasserabsorbierende Zusammensetzung mit verlängerter Lagerfähigkeit und welche die Faserbildung erleichtert.
CA2006386A1 (en) Absorbent material
DE69115765D1 (de) Herstellung von optisch aktiven arylaliphatischen Carbonsäuren
IT8721063A0 (it) Composizione ad attivita'tricogena.
DE3889980D1 (de) Reaktivfarbstoffe, deren Herstellung und Verwendung.
DE68905705D1 (de) Sphaerische phosphoraggregate, ihre herstellung und verwendung in roentgenstrahlschirmen.
ATE90510T1 (de) Antimikrobische zusammensetzung und deren verwendung.
PT86153A (de) Optisch aktive gyrasehemmer ihre herstellung und verwendung als antibiotika
NO902104L (no) Kosmetisk blanding.
ATE45164T1 (de) Steroido(3,2-c>-pyrazole, als antiandrogene und ihre herstellung.
ITRM920384A1 (it) Procedimento per la produzione di leuco coloranti allo zolfo e prodotto ottenuto.
EP0409369A3 (en) Substituted pyrimidinyloxy-(thio)-and triazinyloxy-(thio)acrylic acid derivatives, process for their preparation and their use as an agent with herbicidic, fungicidic and plantgrowth regulating activity
DE3868287D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.
DE3872337D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.
DE3865049D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.
DE68912083D1 (de) Substituierte Karbonsäuren, ihre Herstellung und Verwendung.
DE3868104D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties